Bank of America Invests in GLP-1 Medications for Employees
Bank of America CEO Brian Moynihan announced that the second-largest U.S. bank spends $250 million annually to provide GLP-1 medications (weight loss drugs) to its employees. This investment in employee wellness is likely to be of interest to financial institutions and other large employers in Europe.